Owing to their structural similarities, teixobactin and clovibactin are suggested to have anti-breast cancer effects, potentially through the inhibition of histone deacetylases (HDAC) and modulation of the mechanistic target of rapamycin complex 1 (mTORC1) pathway. The gene discussed is HDAC9; the disease is breast carcinoma.